JP2019521105A - 補体ｃ５多型を有する患者を治療するための抗ｃ５抗体 - Google Patents

補体ｃ５多型を有する患者を治療するための抗ｃ５抗体 Download PDF

Info

Publication number
JP2019521105A
JP2019521105A JP2018563888A JP2018563888A JP2019521105A JP 2019521105 A JP2019521105 A JP 2019521105A JP 2018563888 A JP2018563888 A JP 2018563888A JP 2018563888 A JP2018563888 A JP 2018563888A JP 2019521105 A JP2019521105 A JP 2019521105A
Authority
JP
Japan
Prior art keywords
antibody
patient
antigen
binding fragment
polymorphism
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018563888A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019521105A5 (enExample
Inventor
ミュラースハウゼン，フロリアン
ミルトン，マーク
ンゴジ アヌナ ジョンソン，レスリー
ンゴジ アヌナ ジョンソン，レスリー
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2019521105A publication Critical patent/JP2019521105A/ja
Publication of JP2019521105A5 publication Critical patent/JP2019521105A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2018563888A 2016-06-07 2017-06-01 補体ｃ５多型を有する患者を治療するための抗ｃ５抗体 Pending JP2019521105A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662346683P 2016-06-07 2016-06-07
US62/346,683 2016-06-07
PCT/IB2017/053245 WO2017212375A1 (en) 2016-06-07 2017-06-01 Anti-c5 antibody for treating patients with complement c5 polymorphism

Publications (2)

Publication Number Publication Date
JP2019521105A true JP2019521105A (ja) 2019-07-25
JP2019521105A5 JP2019521105A5 (enExample) 2020-07-09

Family

ID=59078125

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018563888A Pending JP2019521105A (ja) 2016-06-07 2017-06-01 補体ｃ５多型を有する患者を治療するための抗ｃ５抗体

Country Status (5)

Country Link
US (1) US20190225678A1 (enExample)
EP (1) EP3464351A1 (enExample)
JP (1) JP2019521105A (enExample)
CN (1) CN109328197A (enExample)
WO (1) WO2017212375A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022553377A (ja) * 2019-10-25 2022-12-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｃ５関連疾患の治療または予防のための投与レジメン

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY196006A (en) 2016-06-14 2023-03-06 Regeneron Pharma Anti-C5 Antibodies and Uses Thereof
KR20200098528A (ko) 2017-12-13 2020-08-20 리제너론 파아마슈티컬스, 인크. 항-c5 항체 조합물 및 이의 용도
MX2022001896A (es) 2019-08-16 2022-06-02 Regeneron Pharma Formulaciones anti-c5 de alta concentracion.
CN118251491A (zh) 2021-10-28 2024-06-25 瑞泽恩制药公司 用于敲除C5的CRISPR/Cas相关方法及组合物
CN119409815B (zh) * 2025-01-07 2025-04-08 天辰生物医药(苏州)有限公司 抗人补体c5 vhh抗体及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010521194A (ja) * 2007-03-22 2010-06-24 ノバルティス アーゲー Ｃ５抗原およびその使用
JP2011529700A (ja) * 2008-08-05 2011-12-15 ノバルティス アーゲー 補体タンパク質ｃ５を標的とする抗体に関する組成物および方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0985039B1 (en) 1997-06-12 2008-02-20 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
CA2742802C (en) * 2008-11-10 2019-11-26 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
EP2563813B1 (en) * 2010-04-30 2015-08-26 Alexion Pharmaceuticals, Inc. Anti-c5a antibodies and methods for using the antibodies
TW201418707A (zh) * 2012-09-21 2014-05-16 Alexion Pharma Inc 補體組分ｃ５拮抗劑之篩選分析
KR101638931B1 (ko) * 2013-01-31 2016-07-12 서울대학교산학협력단 보체 관련 질환의 예방 및 치료를 위한 ｃ5 항체 및 방법
GB201410116D0 (en) * 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
WO2016117346A1 (en) * 2015-01-22 2016-07-28 Chugai Seiyaku Kabushiki Kaisha A combination of two or more anti-c5 antibodies and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010521194A (ja) * 2007-03-22 2010-06-24 ノバルティス アーゲー Ｃ５抗原およびその使用
JP2011529700A (ja) * 2008-08-05 2011-12-15 ノバルティス アーゲー 補体タンパク質ｃ５を標的とする抗体に関する組成物および方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MORGAN, B. P., HARRIS, C. L.: "Complement, a target for therapy in inflammatory and degenerative diseases", NATURE REVIEWS. DRUG DISCOVERY, vol. 14, no. 12, JPN6021021477, December 2015 (2015-12-01), pages 857 - 877, ISSN: 0004524407 *
NISHIMURA, J. ET AL.: "Genetic variants in C5 and poor response to eculizumab", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 370, no. 7, JPN6021021476, 2014, pages 632 - 639, ISSN: 0004524406 *
西村 純一: "C5遺伝子多型と発作性夜間血色素尿症(PNH)治療薬エクリズマブに対する反応不良", 最新医学, vol. 第７０巻，第８号, JPN6021021475, August 2015 (2015-08-01), pages 1716 - 1721, ISSN: 0004524405 *
西村 純一: "発作性夜間血色素尿症(PNH)の補体がかかわる最新の話題と抗補体療法の未来−C5遺伝子多型によるエクリズマ", 医学のあゆみ, vol. 第２５７巻，第８号, JPN6021021474, 21 May 2016 (2016-05-21), pages 827 - 831, ISSN: 0004608045 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022553377A (ja) * 2019-10-25 2022-12-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｃ５関連疾患の治療または予防のための投与レジメン

Also Published As

Publication number Publication date
WO2017212375A1 (en) 2017-12-14
US20190225678A1 (en) 2019-07-25
CN109328197A (zh) 2019-02-12
EP3464351A1 (en) 2019-04-10

Similar Documents

Publication Publication Date Title
JP7210629B2 (ja) 抗補体Ｃ１ｓ抗体とそれらの用途
JP7227312B2 (ja) 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体およびその使用
TWI634126B (zh) 抗－N3pGlu 類澱粉β肽抗體及其用途
US20190225678A1 (en) Anti-c5 antibody for treating patients with complement c5 polymorphism
RU2771384C2 (ru) Фармацевтическая композиция, содержащая антитело к lag-3, и ее применение
WO2019062832A1 (zh) Tigit抗体、其抗原结合片段及医药用途
WO2016137811A1 (en) Antibodies to tau and uses thereof
JP2020511469A (ja) 補体が媒介する疾患および障害を処置するための方法
JP2023535384A (ja) 抗ｐｄ－１抗体医薬組成物及びその用途
US20210261663A1 (en) Anti-tim3 antibody pharmaceutical composition and use thereof
JP2024503724A (ja) 免疫調節抗体およびその使用
CN113754763B (zh) 分离的抗原结合蛋白及其用途
WO2023025249A1 (zh) 一种含融合蛋白的药物组合物
JP7755895B2 (ja) 単離された抗原結合タンパク質及びその使用
HK40063408A (en) Anti-complement c1s antibodies and uses thereof
HK1261836B (en) Anti-complement c1s antibodies and uses thereof
HK40025348B (en) Lag-3 antibody pharmaceutical composition and use thereof
EA041243B1 (ru) Антитела к бета-амилоидному пептиду n3pglu и их применение

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200525

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200525

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210608

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211005